Shalash Ali, Belal Nourhan, Zaki Amr S, Georgy Shady S, Doheim Mohamed Fahmy, Hazzou Ahmed, Abdelnasser Azza
Department of Neurology, Faculty of Medicine, Ain Shams University, 168 Elnozha St, Saint Fatima Square, Heliopolis, Cairo, Egypt.
Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):153. doi: 10.1186/s41983-022-00582-7. Epub 2022 Dec 9.
The COVID-19 vaccine-related Guillain-Barré syndrome (GBS) has been described for both messenger-RNA vaccine and adenovirus-vectored types in a few cases with great public concern and the necessity to inform physicians about the variations of its presentations given its life-threatening consequences.
This case series highlighted the presentation with GBS following different COVID-19 vaccinations in seven cases with ages ranging from 29 to 59 years. Three patients received the AstraZeneca vaccine, two received the Pfizer vaccine, one received Sinopharm, and one received the Janssen vaccine. Latency ranged from 5 to 60 days and cases achieved either partial or complete improvement after treatment trials. Patients responded to plasmaphereses, but not pulse steroid therapy.
This case series highlights the variable presentations and outcomes of GBS following different COVID-19 vaccination from one center. The early identification and appropriate management of such cases can lead to better outcomes.
新冠病毒疫苗相关格林-巴利综合征（GBS）在少数使用信使核糖核酸疫苗和腺病毒载体疫苗的病例中已有报道，引起了公众的极大关注，鉴于其危及生命的后果，有必要告知医生其临床表现的差异。
本病例系列突出了7例年龄在29至59岁之间、接种不同新冠病毒疫苗后出现GBS的临床表现。3例患者接种了阿斯利康疫苗，2例接种了辉瑞疫苗，1例接种了国药疫苗，1例接种了杨森疫苗。潜伏期为5至60天，经治疗试验后，病例均有部分或完全改善。患者对血浆置换有反应，但对脉冲类固醇疗法无反应。
本病例系列突出了来自一个中心的不同新冠病毒疫苗接种后GBS的不同临床表现和结果。对此类病例的早期识别和适当管理可带来更好的结果。
